Figures
1. Swimmer plot showing the clinical course of each patient over time. Each bar represents one patient treated with venetoclax, color-coded based on diagnosis (AML, pink; B-ALL, green; MDS, blue). Dates of severe infection, hematopoietic stem cell transplantation (HSCT), disease progression, or death are depicted by symbols. Therapy combined with venetoclax are shown on the left with a white box (hypomethylating agent, HMA) or black box (chemotherapy). Response to therapy is depicted in the second column to the left: circles are filled (complete response, CR), partially filled (partial response, PR), empty (stable disease, SD), or contain an “X” (PD, progressive disease)
2. One-year overall and progression-free survival for 13 patients treated with venetoclax combination therapy